Comparison of long-term efficacy, tolerability and drug survival rates of baricitinib as monotherapy or combination therapy in RA patients: Data from a real-world prospective cohort study
RMD Open 2025;11:e006333 Doi: 10.1136/rmdopen-2025-006333
Temiz et al. showed that this long-term data provides strong evidence that BARI maintains its clinical efficacy, drug survival and acceptable safety profile as monotherapy over several years in a real-world setting. Authors evaluated the long-term efficacy, drug survival and safety of BARI monotherapy versus combination therapy in a prospective cohort of patients with RA.